Asher Kornbluth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Asher Kornbluth has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
James George
5 shared publications- Peter Legnani
Mount Sinai Hospital
5 shared publications - Thomas A. Ullman
The Henry D. Janowitz Division of Gastroenterology, Department of Medicine
4 shared publications - Jean-Frederic Colombel
Hopital Huriez, CHRU, Lille, Nord, France
3 shared publications Marla Dubinsky
3 shared publications- Adam F Steinlauf
Mount Sinai School of Medicine, Mount Sinai Hospital, 12 East 86th Street, New York, NY 10028, USA
2 shared publications
Latest Publications
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6) , S-818-818
Mo1832 - Baseline Level of Integrin A4B7 on Circulating Plasmablasts Predicts Response to Vedolizumab in Patients with Inflammatory Bowel Disease
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6) , S-818-818
Mo1832 - Baseline Level of Integrin A4B7 on Circulating Plasmablasts Predicts Response to Vedolizumab in Patients with Inflammatory Bowel Disease
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S585
Su1907 Exploring MEChanisms of IBD traNsmission In Utero through the Microbiome: The MECONIUM Study Pilot
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S585
Su1907 Exploring MEChanisms of IBD traNsmission In Utero through the Microbiome: The MECONIUM Study Pilot
- 31 May 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (5)
557 Colectomy Rate in Hospitalized Ulcerative Colitis Patients Undergoing Therapy with Cyclosporine (CsA)
- 31 May 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (5)
557 Colectomy Rate in Hospitalized Ulcerative Colitis Patients Undergoing Therapy with Cyclosporine (CsA)
- Open Access
- 1 March 2007
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 13 (3) , 362-363
Endoscopic management of intestinal strictures in Crohnʼs disease
- 1 March 2007
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 13 (3) , 362-363
Open AccessEndoscopic management of intestinal strictures in Crohnʼs disease
- 1 June 2004
- Published by Springer Nature in Current Treatment Options in Gastroenterology
- Vol. 7 (3) , 161-167
Newer therapies for inflammatory bowel disease
Recent controlled and uncontrolled trial data in inflammatory bowel disease have suggested several new avenues of possible therapies and refined our understanding of the uses and selectiveness of anti-tumor necrosis factor (TNF)-based therapies. Infliximab remains the only proven effective anti-TNF therapy, whereas others have proven ineffective (etanercept, CDP-571) or of limited utility (thalidomide, CDP-870). A Crohn’s disease Clinical trial Evaluating infliximab in a New long-term Treatment regimen (ACCENT I) and ACCENT II trials supported the strategy of using 5 to 10 mg/kg of infliximab on an every 8-week basis for maintenance of remission, although in clinical practice many physicians take variable approaches to maintenance of remission dosing schedules. On the other hand, no controlled trial data to date have supported the use of infliximab in ulcerative colitis. Therapies utilizing novel mechanistic approaches, such as hematopoietic growth factors, mitogen-activated protein (MAP)-kinase inhibition, and peroxisome proliferator activated receptor gamma ligand receptor binding have shown promise in small uncontrolled trials and await confirmation of their utility in randomized, placebo-controlled trials. Newer biologic (natalizumab) or cytokine-based therapies (monoclonal antibody to interleukin-6) have shown preliminary evidence of efficacy in controlled trials, but neither have yet been approved by the US Food and Drug Administration and, therefore, have not been commercialized. However, tacrolimus, a potent calcineurin inhibitor and inhibitor of interleukin-2 expression, has shown efficacy in Crohn’s disease, albeit at the cost of substantial potential toxicity.
- 1 June 2004
- Published by Springer Nature in Current Treatment Options in Gastroenterology
- Vol. 7 (3) , 161-167
Newer therapies for inflammatory bowel disease
Recent controlled and uncontrolled trial data in inflammatory bowel disease have suggested several new avenues of possible therapies and refined our understanding of the uses and selectiveness of anti-tumor necrosis factor (TNF)-based therapies. Infliximab remains the only proven effective anti-TNF therapy, whereas others have proven ineffective (etanercept, CDP-571) or of limited utility (thalidomide, CDP-870). A Crohn’s disease Clinical trial Evaluating infliximab in a New long-term Treatment regimen (ACCENT I) and ACCENT II trials supported the strategy of using 5 to 10 mg/kg of infliximab on an every 8-week basis for maintenance of remission, although in clinical practice many physicians take variable approaches to maintenance of remission dosing schedules. On the other hand, no controlled trial data to date have supported the use of infliximab in ulcerative colitis. Therapies utilizing novel mechanistic approaches, such as hematopoietic growth factors, mitogen-activated protein (MAP)-kinase inhibition, and peroxisome proliferator activated receptor gamma ligand receptor binding have shown promise in small uncontrolled trials and await confirmation of their utility in randomized, placebo-controlled trials. Newer biologic (natalizumab) or cytokine-based therapies (monoclonal antibody to interleukin-6) have shown preliminary evidence of efficacy in controlled trials, but neither have yet been approved by the US Food and Drug Administration and, therefore, have not been commercialized. However, tacrolimus, a potent calcineurin inhibitor and inhibitor of interleukin-2 expression, has shown efficacy in Crohn’s disease, albeit at the cost of substantial potential toxicity.
- Open Access
- 1 May 2004
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 10 (3) , 278-285
Video Capsule Endoscopy in Inflammatory Bowel Disease
In this paper, we critically review the rationale, technical issues, and diagnostic findings, difficulties in interpretation, complications, potential
- 1 May 2004
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 10 (3) , 278-285
Open AccessVideo Capsule Endoscopy in Inflammatory Bowel Disease
In this paper, we critically review the rationale, technical issues, and diagnostic findings, difficulties in interpretation, complications, potential
- Open Access
- 1 May 2003
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 9 (3) , 194-197
Is There Still a Role for Cyclosporine in the Treatment of Inflammatory Bowel Disease? Pro Argument
I found the title of this episode of Controversies in IBD—“Is There Still a Role for Cyclosporine in the Treatment of Inflammatory Bowel Disease? Pro Argument”—a bit perplexing. When did cyclosporine (CSA) ever cease to have a role in inflammatory bowel disease (IBD)? Is one to suppose that the surgery for ulcerative colitis (UC) has become so refined that all patients undergoing surgery for severe colitis are rendered “cured” of their chronic intestinal ailments? Or should we believe that, despite the lack of controlled trial evidence in severe UC, infliximab has already become an acceptable alternative to cyclosporine or surgery? For patients with severe UC who do not benefit from steroid treatment, both randomized controlled trial data and extensive open-label experience demonstrate the consistent efficacy of CSA, albeit at a stiff cost. For patients with the far less frequent Crohn's disease (CD) who do not benefit from any medical therapy, including infliximab, and are confronted with limited surgical options, CSA clearly remains an important option as well.
- 1 May 2003
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 9 (3) , 194-197
Open AccessIs There Still a Role for Cyclosporine in the Treatment of Inflammatory Bowel Disease? Pro Argument
I found the title of this episode of Controversies in IBD—“Is There Still a Role for Cyclosporine in the Treatment of Inflammatory Bowel Disease? Pro Argument”—a bit perplexing. When did cyclosporine (CSA) ever cease to have a role in inflammatory bowel disease (IBD)? Is one to suppose that the surgery for ulcerative colitis (UC) has become so refined that all patients undergoing surgery for severe colitis are rendered “cured” of their chronic intestinal ailments? Or should we believe that, despite the lack of controlled trial evidence in severe UC, infliximab has already become an acceptable alternative to cyclosporine or surgery? For patients with severe UC who do not benefit from steroid treatment, both randomized controlled trial data and extensive open-label experience demonstrate the consistent efficacy of CSA, albeit at a stiff cost. For patients with the far less frequent Crohn's disease (CD) who do not benefit from any medical therapy, including infliximab, and are confronted with limited surgical options, CSA clearly remains an important option as well.